USPTO serial 77388972
THG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PINO, BRIAN
- Law office
- TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with THG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa A. Osman
Lisa A. Osman Dorsey & Whitney LLP370 Seventeenth Street, Suite 4700IP DepartmentDenver, CO 80202-5647Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Advisory services relating to diagnostic preparations and products, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of Psychiatric diseases and disorders, and consulting and advisory services relating to the provision of goods containing reagents for use in the collection and testing of DNA, RNA and bodily tissues; advisory services relating to diagnostic apparatus and diagnostic instruments, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for diseases and disorders of the central nervous system, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for psychiatric diseases and disorders, consulting and advisory services relating to the development, testing and efficacy, of apparatus and diagnostic instruments for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of psychiatric diseases and disorders, in connection with assays or assay kits for use in the collection and testing of DNA, RNA and bodily tissues, and in connection with assay kits (which may contain reagents) for use in the collection of DNA, RNA and bodily tissues; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for disorders of the central nervous system; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for psychiatric disorders; design and control of pharmacogenetic diagnostic tests for disorders and diseases of the central nervous system; design and control of pharmacogenetic diagnostic tests for psychiatric diseases and disorders; design and control of pharmacogenetic tests, including the devising, compiling and testing of algorithms and mathematical systems for predicting response to a pharmaceutical product based on individual genetic profile; scientific research related to pharmacogenetics; research and advisory services relating to pharmaceuticals | ACTIVE | — |
| 044 | Medical diagnostic services; diagnostic testing relating to the human body, namely, diagnostic testing and analysis of samples, in order to predict response of individuals to pharmaceutical products and treatments for disorders of the central nervous system, diagnostic testing and analysis of samples in order to predict response of individuals to pharmaceutical products and treatments for psychiatric disorders, diagnostic testing and analysis of samples in order to confirm diagnosis of diseases and disorders of the central nervous system, and diagnostic testing and analysis of samples in order to confirm diagnosis of Psychiatric diseases and disorders; clinical services, namely, the analysis of samples of DNA, RNA and bodily tissues in order to prescribe the pharmaceutical product or treatment best suited to the patient (i.e. the pharmaceutical product likely to have the most beneficial effect and/or the one with fewest or least severe side effects), the taking of samples of bodily tissues for analysis in connection with the prescription of pharmaceuticals, or other medical treatment, and medical and scientific research in the nature of conducting clinical trials; compilation of medical reports, relating to prediction of response of individuals to pharmaceutical products and treatments for disorders of the central nervous system; compilation of medical reports, relating to confirmation of diagnosis of diseases and disorders of the body, and prescription of most efficient and efficacious pharmaceutical product or method for treatment thereof; compilation of medical reports, namely, a resource of phenotypic and genotypic data relating to diseases and disorders of the central nervous system and psychiatric diseases and disorders; conducting of medical examinations for diagnosis of treatments; testing and profiling for medical purposes; computer aided diagnostic testing services relating to the human body | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 19, 2010 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 19, 2010 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 23, 2009 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 23, 2009 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 23, 2009 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 23, 2009 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 23, 2008 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 23, 2008 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 23, 2008 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 23, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 23, 2008 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 23, 2008 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 23, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 11, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 9, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 24, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 24, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 24, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 7, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 5, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 6, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 5, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 19, 2008 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 13, 2008 | ALIE | ASSIGNED TO LIE | — |
| Feb 15, 2008 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 9, 2008 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Feb 8, 2008 | NWAP | NEW APPLICATION ENTERED | — |